|Articles|May 5, 2003
Comparative study finds early vision benefits for intravitreal triamcinolonetreatment of occult CNV
Ft. Lauderdale-Results from a prospective, comparative study indicateintravitreal triamcinolone acetonide 25 mg may improve visual outcome insome patients with exudative AMD, reported Jost B. Jonas, MD, of the Universityof Heidelberg, Germany.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA grants IDE approval to EyeYon Medical for its US clinical study of EndoArt
2
Ocular Therapeutix accelerates NDA submission plans for AXPAXLI for wet AMD
3
First patient treated in ViaLase’s IDE trial
4
Formosa Pharmaceuticals and Rxilient sign licensing and commercialization agreement for APP13007
5











































.png)


